pharma news today glp-1 obesity drug updates Agonists Weight Loss Drugs Market Report, 2025-2030 GLP-1 Antagonists Increase Plan Drug

Host-microbe-drug-nutrient screen identifies bacterial effectors of metformin therapy

"BPC 157 counteracts the effects of dopaminergic lesions." J Physiol

To maintain the pressure, the Berendsen pressure coupling 47 was used in the pre-equilibrium run, and the Parrinello-Rahman pressure coupling 48,49 was used in the equilibrium and production run, with the pressure time constant and isothermal compressibilities set to 2 ps and 4.5 10 5 bar 1 , respectively

How many people are using GLP-1 medications By 2022, semaglutide become the dominant GLP-1 medication, accounting for 54% of use among adults with diabetes and 65% among adults without diabetes, the study noted

The MetabolicPsychiatric Interface of Addiction Another core pillar of NRIs GLP-1 research focuses on the metabolic disruptions that frequently accompany opioid use disorder

Efficacy of oral cholecalciferol on rhododendrolinduced vitiligo: a blinded randomized clinical trial